Back to Results

Biostem Technologies Inc (BSEM)

Featured in High-Beta Momentum

BioStem Technologies, Inc. is a common stock listing on OTC Markets for a U.S.-based healthcare company focused on placental-derived allografts used in advanced wound care and regenerative therapies. The company develops, manufactures, and commercializes products including Vendaje, Vendaje AC, Vendaje OPTIC, American Amnion AC, and American Amnion. These products are used as protective coverings for soft tissue wounds, ocular surface repair, and homologous tissue applications. BioStem Technologies was incorporated in 2006, adopted its current name in August 2014, and is headquartered in Fort Lauderdale, Florida.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Altman Z-Score Free Cash Flow / Net Income
OTC-BSEM
$4.14
24.1% Upside
Undervalued
$7
110.0% Upside
Bargain
Good
0.0%
1.8x
1.5x
57.755 M
47.331 M
5.4%
-0.1
-9.6%
Valuation • Fair Value

Biostem Technologies Inc (OTC-BSEM) Fair Value by Valuation Model

Review the available estimates for Biostem Technologies Inc (OTC-BSEM), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$4.14

Estimated upside of 24.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$3.98

Earnings power value estimate.

Comps Fair Value

$4.17

Comparable-company valuation reference.

Analyst Price Target

$7

Analysts imply upside of 110.0%.

How to read these valuation models

Use the 5 available valuation references for Biostem Technologies Inc (OTC-BSEM) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biostem Technologies Inc (OTC-BSEM)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

37.651 M

Current operating scale indicator.

Revenue Forecast

29.004 M

Forward revenue estimate.

EBITDA

-14.117 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Biostem Technologies Inc (OTC-BSEM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biostem Technologies Inc (OTC-BSEM)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

14.11

Higher caution zone on this screen.

Altman Z-Score

-0.1

Lower score that deserves closer risk review.

FCF / Net Income

-9.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biostem Technologies Inc (OTC-BSEM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Biostem Technologies Inc (OTC-BSEM)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Biostem Technologies Inc (OTC-BSEM). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Biostem Technologies Inc (OTC-BSEM) Stock Forecast & Technical Outlook

Review Biostem Technologies Inc (OTC-BSEM) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Biostem Technologies Inc (OTC-BSEM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Biostem Technologies Inc (OTC-BSEM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Biostem Technologies Inc (OTC-BSEM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Biostem Technologies Inc (OTC-BSEM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Biostem Technologies Inc (OTC-BSEM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Biostem Technologies Inc (OTC-BSEM)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Biostem Technologies Inc (OTC-BSEM) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Biostem Technologies Inc (OTC-BSEM) Stock FAQ

Data-supported answers about Biostem Technologies Inc (OTC-BSEM), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$4.14
Estimated upside 24.1%
Valuation Rating
Undervalued
Estimated upside of 24.1%
Analyst Target
$7
Implied upside 110.0%
Financial Health
Good
Current financial-health read

The current fair value estimate for Biostem Technologies Inc (OTC-BSEM) is $4.14. This implies an estimated upside of 24.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 24.1% versus the current market price.

The available analyst price target for Biostem Technologies Inc (OTC-BSEM) is $7. The analyst target implies estimated upside of 110.0%.

The current financial health read for Biostem Technologies Inc (OTC-BSEM) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Biostem Technologies Inc (OTC-BSEM).

The current market capitalization listed for Biostem Technologies Inc is 57.755 M.

The current enterprise value listed for Biostem Technologies Inc is 47.331 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biostem Technologies Inc is OTC-BSEM, and the stock is listed on OTC Markets.

Biostem Technologies Inc (OTC-BSEM) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Biostem Technologies Inc is 5.4%, which helps investors evaluate the company’s financing structure and leverage profile.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B